Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385907 | 0.88 | PIK3CD (0.51) | GPR119PIK3CDPIK3CA | |
| SCHEMBL391304 | 0.88 | GPR119 (0.58) | GPR119 | |
| SCHEMBL1830976 | 0.84 | GPR119 (0.45) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL4720958 | 0.84 | GPR119 (0.46) | GPR119PIK3CDCDK2FLT3CDK6 | |
| SCHEMBL4720662 | 0.84 | PIK3CA (0.42) | GPR119PIK3CDPIK3CAERBB2CDK2 | |
| SCHEMBL5048543 | 0.82 | FLT3 (0.39) | GPR119PIK3CDCDK2FLT3CDK6 | |
| SCHEMBL1070555 | 0.79 | GPR119 (0.47) | GPR119CDK2FLT3CDK6 | |
| SCHEMBL5048764 | 0.79 | GPR119 (0.49) | GPR119ERBB2CDK2FLT3CDK6 | |
| SCHEMBL392230 | 0.77 | GPR119 (0.49) | GPR119 | |
| SCHEMBL391329 | 0.76 | GPR119 (0.49) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |